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ABSTRACT
Introduction: Patients undergoing structural
heart interventions often require large-sized
sheath insertion into femoral arteries and
veins. Clinical outcome data on the use of
suture-mediated devices for large femoral
arterial access in structural heart interventions
is limited. We assessed the efficacy of the
PercloseTM (Abbott Vascular Devices, Santa
Clara, CA, USA) suture-mediated device using
the pre-closure technique in achieving
hemostasis in femoral arterial access sites
following large sheath insertion (C8 Fr).
Methods: One hundred consecutive patients
underwent 101 femoral artery access sites
closures with the Perclose device using the
pre-closure technique. Sixty-two percent of the
patients were male and their mean (SD) age was
52 (±26) years. All patients received heparin.
Results: Mean arterial access site sheath
diameter was 13± 2 Fr. Immediate hemostasis
was achieved in 96/101 (96%) procedures
(B2 min). Two patients (2%) had access site-
related complications requiring further
interventions. On clinical follow up [mean (SD)
follow-up of 24 (±12) months and median
follow-up of 8.5 months], no complications
were seen in the arterial access sites.
Conclusion: Pre-closure of large-size femoral
arterial access sheath sites using the suture-
mediated Perclose device is efficacious in
achieving rapid hemostasis in patients
undergoing structural interventions. On 1-year
follow-up, there were no arterial access site
complications requiring further investigations
or interventions.
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INTRODUCTION
Patients undergoing structural and congenital
heart interventions usually require large-sized
sheath insertion into the femoral arteries. This
may increase the risk of developing access site
vascular complications. Hence, active
management of the femoral access site can
potentially reduce the risk of vascular
complications and allow early mobilization and
discharge.Theuseofarterial closuredevices iswell
established inpatientsundergoingdiagnostic and
percutaneous coronary interventions [1],
percutaneous aortic balloon valvuloplasty
(PABV) [2], and endovascular aortic procedures
[3]. The use of the PercloseTM (Abbott Vascular
Devices, Santa Clara, CA, USA) device in venous
access sites has also beendescribed [4–7].Here, we
describe the use of the Perclose suture-mediated
device using the pre-closure technique in a series
of 101 femoral arterial access site closures in
patients undergoing congenital and structural
heart interventions.
METHODS
Data from 100 consecutive patients who
underwent large femoral arterial access (C8 Fr)
site closures for congenital and structural
interventions were analyzed retrospectively.
Time to hemostasis, mobilization, and need
for further intervention at the access site were
analyzed. Patients had clinical follow-up
reviews at 3 months and at 9–12 months. At
follow-up, vascular assessment included
checking for the femoral pulses, presence of
hematoma, or signs of arterial occlusion. All the
procedures were performed in a tertiary cardiac
center, where there were vascular interventional
and surgical services available. Patients with
previous multiple vascular access, who had
difficult arterial access due to extensive
scarring, did not receive the Perclose device.
Major complications related to device were
defined as theneed forperi-procedural surgical or
radiological intervention or bleeding requiring
blood transfusion. The Perclose device efficacy
was defined as achievement of hemostasis at the
femoral arterial access site in B2 min following
sheath removal and deployment of the pre-
deployed sutures without the need for further
manual compression.
Pre-closure Technique
Femoral arterial access was obtained by Seldinger
technique [7]. After wire insertion, a 6 Fr dilator
was used for dilatation. Subsequently, a 6 Fr
Perclose (A-T or Proglide; Abbott Vascular
Devices) device was inserted and the wire was
removed. Spontaneous blood flow through the
side port was observed. The footplate of the
device was deployed and the device pulled back
and sutures set as usual. The footplates were
released and the device partially retrieved until
the port for the guide wire was visible (Figs. 1, 2).
The guide wire was reintroduced into the artery
and the device removed. An appropriately sized
sheath was inserted. Upsizing of sheaths as
Fig. 1 Insertion of 6 Fr dilator over the wire following
femoral vessel access
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required was performed using normal
techniques. The sutures were tightened at the
end of the procedure upon removal of the
sheath(s) from the vessel.
A single Perclose device was deployed for
each arterial access up to 12 Fr and two devices
were pre-deployed at right angles to each other
when sheath size was expected to be greater
than 12 Fr. Fourteen patients who underwent
transcatheter aortic valve implantation (TAVI)
had two devices used per procedure.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed written consent for
the procedure was obtained from all patients.
RESULTS
A total of 101 femoral arterial sites closures were
performed in 100 consecutive patients over a
period of 4 years. Of these, 14 underwent TAVI,
39 had PABV, and 47 underwent coarctation of
the aorta (CoA) stenting. Sixty-twopercent of the
patients were male and their mean (SD) age was
52 (±26) years (range 16–95 years). Seventy-
seven (77%) patients were hypertensive. All
received anticoagulation with heparin during
the procedure with a standard dose of 5,000 IU.
The size of the sheaths used during the procedure
ranged from 8 to 18 Fr with a mean (SD) arterial
sheath diameter of 13 (±2) Fr. Final sheath sizes
were 12 Fr in 86 patients and 14 Fr in 14 patients.
Post-procedural Outcomes
Immediate hemostasis was achieved successfully
in 96/101 (96%) procedures. All patients were
mobilized in 2 h except for patients requiring
general anesthesia who were mobilized after 4 h.
Major complications in the form of
pseudoaneurysm were seen in two patients
(2%). One required open vascular repair 2 weeks
following the procedure, while the second was
treated with thrombin injection. Five patients
had mild access site oozing requiring manual
compression for less than 30 min on the arterial
access site. In five cases, the device failed to
deploy on pre-closure initially, necessitating the
use of a further device. There were two deaths in
patients who underwent PABV. Both procedures
were done as emergency procedures after
presenting with cardiogenic shock in the
setting of severe aortic stenosis. One patient
died following TAVI after 7 days related to heart
failure. None of the deaths were related to
vascular access site complications and there was
no significant drop in hemoglobin levels
requiring a blood transfusion.
Follow-up
Ninety-six percent had clinical follow-up
available with a mean (SD) follow-up of 24
(±12) months and median follow-up of
Fig. 2 Rewiring of the vessel following pre-deployment of
the PercloseTM (Abbott Vascular Devices, Santa Clara,
CA, USA) device
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8.5 months. There was no clinical evidence of
access site infection or hematoma. There was no
clinical evidence of limb ischemia and femoral
pulses were palpable.
DISCUSSION
The Perclose device has been used for femoral
arterial and venous closure in small-sized
sheaths following percutaneous coronary
intervention procedures [1, 3]. The use of
Perclose device leads to early hemostasis, early
sheath removal, and early patient mobilization
[6]. A meta-analysis of 30 studies by Nikolsky
et al. [8] showed that Perclose and AngiosealTM
(St. Jude Medical, St. Paul, MN, USA) were
comparable to mechanical compression in
obtaining arterial hemostasis in the setting of
diagnostic coronary angiography and the risk of
access site complications was similar. As all
these studies were on coronary interventions,
they generally used smaller arterial sheath sizes
(B6 Fr). Studies by Martin et al. [9] and
Bangalore et al. [10] have shown lower
deployment success and higher risk of vascular
complications with Perclose compared with the
Angioseal device. In our study, we had 39
patients, who underwent PABV, in whom we
used 12 Fr sheaths with no vascular access site
complications.
Forty-seven patients underwent successful
Perclose device deployment to achieve
complete homeostasis in patients who
underwent stenting for CoA. To the best of
our knowledge, no previous literature exists on
pre-closure of the access site with the Perclose
device for patients undergoing stenting for CoA.
The American Heart Association currently
recommends the use of femoral artery closure
devices to achieve faster hemostasis, shorter
duration of bed rest, and possibly improved
patient comfort [11]. This study demonstrates
that optimal results can be obtained with pre-
closure using a Perclose device for large-sized
femoral arterial access in a wide range of
congenital and structural heart interventions,
including TAVI where large caliber arterial
sheaths are required for valve implantation.
The use of the Perclose device in securing
hemostasis in the venous access sites has also
been described more recently. Shaw et al. [4]
and Mahadevan et al. [6] have reported the use
of Perclose for femoral venous closure and
maintenance of venous patency as assessed by
Doppler following such closure. A recent study
by Hamid et al. [7] described the successful use
of the device in 310 large femoral venous access
sites (C8 Fr) in 243 patients undergoing
structural heart interventions. Mylonas et al.
[5] reported use of Perclose closure device for
access site management after using 14 Fr
femoral venous sheaths for antegrade PABV.
This study demonstrates that Perclose device
can be used safely and effectively for large-sized
femoral arterial access in a wide range of
congenital and structural heart interventions.
Similarly, we used Perclose devices in TAVI
where large caliber arterial sheaths are required
for valve implantation.
Limitations
This is a retrospective series with no control
group that underwent manual compression or
other form of repair to compare efficacy in a
more objective manner. There may also be the
possibility of operator bias in choosing cases for
pre-closure.
CONCLUSION
Pre-closure with the Perclose suture technique
for femoral arterial sites following the insertion
of large-sized sheaths (8 Fr or above) for cardiac
62 Cardiol Ther (2015) 4:59–63
interventions is safe and effective, with a low
risk of vascular access site complications.
Clinical follow-up showed no significant
complications in the arterial access sites.
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